Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: Association with baseline disease severity and subsequent outcome

JAMA Cardiology

Volumn 2, Issue 9, 2017, Pages 995-1006

  Schelbert, Erik B ^a,b   Fridman, Yaron ^a,b   Wong, Timothy C ^a,b   Abu Daya, Hussein ^a,b   Piehler, Kayla M ^a,b   Kadakkal, Ajay ^a,b   Miller, Christopher A ^c   Ugander, Martin ^d   Maanja, Maren ^d   Kellman, Peter ^e   Shah, Dipan J ^f   Abebe, Kaleab Z ^a   Simon, Marc A ^a   Quarta, Giovanni ^g   Senni, Michele ^g   Butler, Javed ^h   Diez, Javier ^i,j   Redfield, Margaret M ^k   Gheorghiade, Mihai ^l  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^g Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ UNIVERSITY OF NAVARRA   (Spain)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k MAYO CLINIC   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ADVERSE OUTCOME; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EXTRACELLULAR SPACE; FEMALE; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEMODYNAMIC STRESS; HOSPITALIZATION; HUMAN; INTEGRATED HEALTH CARE SYSTEM; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICAL DISEASE BY BODY FUNCTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SYSTOLE; BLOOD; CARDIAC MUSCLE; CARDIOMYOPATHY; CINE MAGNETIC RESONANCE IMAGING; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; FIBROSIS; HEART; HEART STROKE VOLUME; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR;

ADULT; AGED; CARDIOMYOPATHIES; COHORT STUDIES; DISEASE PROGRESSION; EXTRACELLULAR SPACE; FEMALE; FIBROSIS; HEART; HEART FAILURE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS;

EID: 85032642734     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.2511     Document Type: Article

References (30)

1. Schelbert EB, Wong TC, Gheorghiade M. Think small and examine the constituents of left ventricular hypertrophy and heart failure: cardiomyocytes versus fibroblasts, collagen, and capillaries in the interstitium. J Am Heart Assoc. 2015;4(9):e002491.
2. Schelbert EB, Sabbah HN, Butler J, Gheorghiade M. Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics. Circ Cardiovasc Imaging. 2017;10(6):e005619.
3. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550-559.
4. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000;36(2):220-225.
5. Kato S, Saito N, Kirigaya H, et al. Impairment of coronary flow reserve evaluated by phase contrast cine-magnetic resonance imaging in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;5(2):e002649.
6. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991; 83(5):1771-1779.
7. Rommel KP, von Roeder M, Latuscynski K, et al. Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2016;67(15):1815-1825.
8. Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247-1259.
9. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102 (12):1388-1393.
10. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105(21): 2512-2517.
11. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83(6):1849-1865.
12. Tamarappoo BK, John BT, Reinier K, et al. Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation. J Am Heart Assoc. 2012;1(3):e001511.
13. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364.
14. Schelbert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J Am Coll Cardiol. 2014;63(21):2188-2198.
15. Schelbert EB, Piehler KM, Zareba KM, et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc. 2015;4(12):e002613.
16. Wong TC, Piehler KM, Kang IA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014;35(10): 657-664.
17. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126(10): 1206-1216.
18. Banypersad SM, Fontana M, Maestrini V, et al. T1 Mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244-251.
19. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112(19):2940-2945.
20. Jeong D, Lee M-A, Li Y, et al. Matricellular protein CCN5 reverses established cardiac fibrosis. J Am Coll Cardiol. 2016;67(13):1556-1568.
21. Heydari B, Abdullah S, Pottala JV, et al. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial. Circulation. 2016;134(5):378-391.
22. Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(40): 2797-2815.
23. Kalogeropoulos A, Psaty BM, Vasan RS, et al; Cardiovascular Health Study. Validation of the health ABC heart failure model for incident heart failure risk prediction: the Cardiovascular Health Study. Circ Heart Fail. 2010;3(4):495-502.
24. Wong TC, Piehler K, Puntil KS, et al. Effectiveness of late gadolinium enhancement to improve outcomes prediction in patients referred for cardiovascular magnetic resonance after echocardiography. J Cardiovasc Magn Reson. 2013; 15:6.
25. Piehler KM, Wong TC, Puntil KS, et al. Free-breathing, motion-corrected late gadolinium enhancement is robust and extends risk stratification to vulnerable patients. Circ Cardiovasc Imaging. 2013;6(3):423-432.
26. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570-1579.
27. Schelbert EB, Testa SM, Meier CG, et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson. 2011;13(1):16.
28. Moon JC, Messroghli DR, Kellman P, et al; Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.
29. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456(7224):980-984.
30. Duca F, Kammerlander AA, Zotter-Tufaro C, et al. Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging. 2016;9(12):e005277.